N Latex SAA Assay
Add sensitivity in diagnosis and monitoring of inflammatory processes

COVID-19 virus next to N Latex SAA Assay bottle
N Latex SAA Assay
Download COVID-19 Testing Guide


The Serum Amyloid A (SAA) Assay* for use on Atellica® NEPH 630,* BN™ II, and BN ProSpec® Systems is designed to enhance diagnostic sensitivity for infections.

Parallel determination of CRP and SAA is useful in diagnosing inflammatory processes, especially viral infections, due to a strong rise in its blood concentration within a few hours.1,2

Recent studies show that SAA can be a prognostic marker for decline and death in COVID-19 patients. 3,4,5

Características y Beneficios

The Serum Amyloid A (SAA) Assay* from Siemens Healthineers provides:

  • High specificity based on monoclonal antibodies
  • Fully automated testing for improved workflow
  • A broad initial measuring range (3–200 mg/L) that helps reduce the need for redilutions and supports economical reagent use
  • A complete kit, including reagent, calibrator, controls, and supplementary reagent (SCS Cleaner reagent available separately)
  • The ability to perform parallel determination of SAA and CRP, which can enhance diagnostic sensitivity for infections 2

Uso Clínico

High sensitivity in diagnosis and monitoring of inflammatory processes.

Serum amyloid A (SAA) represents a protein family and is an acute-phase protein mainly produced by the liver in response to proinflammatory cytokines secreted by the activated monocytes/macrophage lineages.

Like C-reactive protein (CRP), SAA determination can be used in the diagnosis and monitoring of inflammatory and infectious processes. In contrast to CRP, SAA levels show a stronger response to viral infections, while CRP responds more strongly to systemic bacterial infections.2

SAA plasma levels can increase up to 1000-fold, for instance, due to the effect of IL-6 in the course of a cytokine storm. First elevations are seen 3–6 hours after an inflammatory stimulus, reaching a peak concentration in 2–3 days.2,6

Mo et al. studied 118 patients with COVID‐19 (102 mild, 16 severe) for the prognostic value of the inflammation markers SAA, CRP, and PCT applying receiver operating characteristic (ROC) curve analysis, a mathematical procedure to determine the predictive value of the cutoff for a test.3

SAA clearly had the highest predictive value for disease progression of the three inflammation markers (AUC = 0.968).

Figure 1. The diagnostic value of inflammatory indicators in predicting acute aggravation of COVID‐19 (orange: SAA, grey: CRP, teal: PCT).3

SAA, as currently understood, is one of the strongest indicators of SARS-CoV-2 inflammation compared to other acute-phase proteins.

Especificaciones Técnicas

Analytical Assay Performance

Assay principleLatex-enhanced immunonephelometry
Sample typeHuman serum, heparinized plasma
Reference range<6.4 mg/L
Initial measuring ranges3.0–200 mg/L
Detection limit0.8 mg/L
Measuring time6 minutes
Onboard reagent stability4 weeks (Atellica NEPH 630* and BN ProSpec Systems)
5 days on BN II System
Calibration frequency1 week (lot-dependent)
PrecisionIntra-assay CV ≤6.2%
Inter-assay CV ≤4.7%
Total CV ≤6.4%


Productos, servicios y recursos relacionados

*Not available for sale in the U.S.

1Li H, et al. SAA is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 (COVID-19). J Infect. 2020; 80:646-55.

2Zhang Y, Zhang J, Sheng H, et al. Acute phase reactant serum amyloid A in inflammation and other diseases. Adv Clin Chem. 2019;90:25-80.

3Mo XN, Su ZQ, Lei CL, et al. Serum amyloid A is a predictor for prognosis of COVID-19. Respirology. 2020;25(7):764-765.

4Cheng L, Yang JZ, Bai WH, et al. Prognostic value of serum amyloid A in patients with COVID-19 [published online ahead of print, 2020 Jul 30]. Infection. 2020;1-8

5Zhang Y, et al. Serum amyloid A protein as a potential biomarker useful in monitoring the course of COVID-19: a retrospectively studied. doi:10.21203/rs.3.rs-19724/v1

6Vietri L, Bennett D, Cameli P, et al. Serum amyloid A in patients with idiopathic pulmonary fibrosis. Respir Investig. 2019;57:430-4.

Atellica, BN, BN ProSpec, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. All other trademarks and brands are the property of their respective owners.